Peju is an innovative operational strategy expert with over 15 years wide-ranging experience relating to strategic programme leadership, planning and management of clinical trials with responsibility for global clinical programmes. She has extensive experience in working in early drug discovery and exploratory phases focused on the transition of early stage assets to clinical development. She has held leadership positions in programme management responsible for key clinical programmes and assets within Eli Lilly, Sanofi Aventis, Pfizer and Takeda. In her current role at BenevolentAI, she is responsible for driving the asset strategy to maximise the value of both early and late phase drug development programmes.
Kevin is a patient data manager for precision medicine activities at BenevolentAI and is responsible for managing information governance concerns for patient-level data and in identifying and acquiring clinical and –omic data sources that would support our drug discovery programmes. Kevin’s interests include bioethics, intellectual property law and better understanding the value chain that shapes the worth and applicability of health data in the field of precision medicine. Most of his work involves coordinating with stakeholders from very different parts of the company.
